2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma
74
Lymphoma, Large B-Cell, Diffuse
55
Lymphoma, Non-Hodgkin
54
Glioblastoma
41
Lymphoma, Mantle-Cell
40
Lymphoma, Follicular
37
Hodgkin Disease
36
Central Nervous System Neoplasms
32
Gliosarcoma
29
Brain Neoplasms
28
Astrocytoma
28
Lymphoma, Large-Cell, Immunoblastic
26
Burkitt Lymphoma
25
Multiple Myeloma
22
Leukemia, Lymphocytic, Chronic, B-Cell
22
Precursor Cell Lymphoblastic Leukemia-Lymphoma
20
Glioma
20
Oligodendroglioma
16
Lymphoma, B-Cell, Marginal Zone
15
Neoplasms, Plasma Cell
14
Leukemia
13
Recurrence
10
Lymphoma, B-Cell
9
Lymphoma, T-Cell
8
Waldenstrom Macroglobulinemia
6
Lymphoma, T-Cell, Cutaneous
6
Leukemia, Myeloid, Acute
6
Ependymoma
6
Lymphoma, T-Cell, Peripheral
5
Lymphoma, Large-Cell, Anaplastic
5
Interventions
Cyclophosphamide
8
Rituximab
7
fludarabine
6
dacetuzumab
6
fludarabine phosphate
5
blinatumomab
4
Bortezomib
4
ibrutinib
3
Melphalan
3
Lenalidomide
3
Ifosfamide
3
Etoposide
3
Dexamethasone
3
Bendamustine Hydrochloride
3
AP 1903 reagent
3
ponatinib
2
cobomarsen
2
Whole-Body Irradiation
2
Vorinostat
2
Vincristine
2
Tacrolimus
2
Prednisone
2
Peripheral Blood Stem Cell Transplantation
2
Patient Reported Outcome Measures
2
Mycophenolic Acid
2
Mesna
2
Doxorubicin
2
Carboplatin
2
Busulfan
2
Brentuximab Vedotin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Immunoproliferative Disorders
×
Carmustine
×
Clear all
NCT02366663
2018-03-12
SPINOZA
City of Hope Medical Center
Phase 3
Terminated
3 enrolled
8 charts